United States: Intellectual Property

A recent survey of over 300 gallery professionals reveals a striking disconnect in the art world: while galleries increasingly adopt AI for operational tasks, the market remains deeply skeptical of AI-generated artwork.

Developing AI capabilities is a strategic focus for every company, with acquisitions one of the primary ways businesses can rapidly move up the technology curve. Here we explore the key issues that boards need to focus on to lock in value and manage risk in AI-related deals

The U.S. Supreme Court's recent decision to decline hearing a case on AI-generated artwork has reinforced a fundamental principle: copyright protection requires human authorship.

Taylor Swift has filed three new trademark applications with the USPTO, including two sound marks featuring her voice saying "Hey, it's Taylor" and "Hey, it's Taylor Swift," plus a visual mark of her iconic stage appearance.

The UK Government’s report on the copyright and AI consultation was recently published. While the report confirms that balancing the interests of copyrights holders and AI developers is a complex exercise, it also provides an indication of likely scenarios to consider in this fast-evolving environment.

The U.S. Department of Justice's Antitrust Division has issued a series of statements and policy guidance clarifying that strong patent rights and antitrust enforcement are complementary forces that together promote innovation. Through recent court filings and official speeches, the DOJ has addressed critical questions about injunctive relief for patent holders, the relationship between standard-essential patents and market power, and the proper boundaries between contract disputes and antitrust violations.

AbbVie advances its SKYRIZI subcutaneous treatment for Crohn's disease with FDA submission, while investing $1.4 billion in a North Carolina manufacturing campus.

FMReps Consulting Enterprises (“FMReps”), a former supplier of software for Ford's certified pre-owned (CPO) vehicle program, has appealed the US District Court for the Eastern District of Michigan's (“EDMI”)...

The Third Circuit affirmed denial of an injunction to prevent a biosimilar manufacturer from launching a biosimilar version of the blockbuster drug, Stelara (ustekinumab), under a third-party’s private label.

Businesses invest heavily to develop and protect their trade secrets – confidential information that derives independent economic value from not being generally known and that is subject to reasonable measures...

A recent survey of over 300 gallery professionals reveals a striking disconnect in the art world: while galleries increasingly adopt AI for operational tasks, the market remains deeply skeptical of AI-generated artwork.

On April 13, 2026, Governor Abigail Spanberger signed SB 170, which amends Virginia Code Section 40.1-28.7:8, effective July 1, 2026, to restrict employers from enforcing a noncompete against an employee discharged without...